Sorrento Therapeutics Announces the FDA IND Clearance of STI-1558, An Oral M(pro) and Cathepsin L Inhibitor to Treat COVID-19GlobeNewsWire • 07/19/22
Scilex Holding Company, a Sorrento Company, Has Entered A Term Sheet to Acquire Ancora Medical Inc.GlobeNewsWire • 07/07/22
Scilex Holding Company, a Sorrento Company, announces that the Honorable Tommy G. Thompson has joined the Scilex Board of DirectorsGlobeNewsWire • 07/05/22
Sorrento Therapeutics, Inc. announces the appointment of the Honorable Tommy G. Thompson, as Covid-19 Special Consultant to Chairman and CEO Henry JiGlobeNewsWire • 06/24/22
Scilex Holding Company, a Sorrento Company, enters into an agreement for an exclusive license with ROMEG Therapeutics, LLC, for the right to commercialize Gloperba®, an FDA-approved prophylactic treatment for painful gout flares in adults, in the US.GlobeNewsWire • 06/14/22
Sorrento Therapeutics Announces First Subject Dosed in a Phase I Clinical Study of STI-1558, an Oral Mpro Inhibitor as a Standalone Treatment and Prevention of COVID-19 Without Co-Administration of Ritonavir BoosterGlobeNewsWire • 06/03/22
Scilex Holding Company, a Sorrento Company, Announces Pre-Emptive Repurchase of $41.4 Million of its Senior Secured NotesGlobeNewsWire • 06/03/22
Scilex Holding Company, a Sorrento Company, announces continued growth in ZTlido® in managed health care plansGlobeNewsWire • 06/02/22
Caris Life Sciences, Prostate Cancer Clinical Trial Consortium and Sorrento Therapeutics Announce Collaboration to Advance Precision Medicine Development Using Comprehensive Genomic ProfilingPRNewsWire • 06/02/22
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. and Levena Biopharma, a Sorrento Company, are to Present Positive Clinical Progress of A166, an Anti-HER2 ADC, in Treating Locally Advanced or Metastatic HER2-Positive Breast Cancer Patients at the ASCO 20GlobeNewsWire • 06/01/22
Scilex, a Sorrento Company, Announces Initiation of a Phase 2 Study to Evaluate the Safety and Efficacy of SP-103 in Subjects with Acute Low Back PainGlobeNewsWire • 05/18/22
Sorrento Therapeutics, Inc. Appoints Former Roche Executive Tammy Reilly to the Board of DirectorsGlobeNewsWire • 05/18/22
Sorrento's License Partner, Lee's Pharm, Announces Full Enrollment of 498 Patients in a Phase III Trial of Socazolimab (Anti-PD-L1 Antibody) for First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)GlobeNewsWire • 05/17/22
Sorrento Announces FDA Authorization to Proceed With Phase 2 Study of Abivertinib (Fujovee™) to Treat Metastatic Castrate Resistant Prostate Cancer (MAVERICK Trial)GlobeNewsWire • 05/17/22
Scilex Holding Company, a Sorrento Company, and Vickers Vantage Corp. I announced today the filing of a Registration Statement on Form S-4 with the Securities and Exchange Commission relating to the previously announced proposed business combination betweGlobeNewsWire • 05/16/22
Scilex, a Sorrento Company, Highlights Safety Data From Phase 1 Trial of SP-104, a Proprietary Low Dose Naltrexone for FibromyalgiaGlobeNewsWire • 05/11/22
Scilex, a Sorrento Company, Announces Pivotal Phase 3 SP-102 (SEMDEXA™) Data Presentation At The American Society Of Interventional Pain (ASIPP) 2022 Annual MeetingGlobeNewsWire • 05/06/22